KRYS Share Price Performance
US$0
-123.36 (-100.00%)
Price US$0
Fair ValueUS$322.78
Share Pricen/a
Narrative Update • May 26
Krystal Biotech, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 63 Fair Values set on narratives written by author
KRYS Community Narratives
AN
Fair Value
·Fair Value US$322.78 5.0% undervalued intrinsic discount
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
Fair Value
·Fair Value US$241 27.2% overvalued intrinsic discount
Uncertain Gene Therapy Dynamics Will Fuel Challenges Yet Spark Hope
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$371 17.4% undervalued intrinsic discount
Aging Populations And AI Will Accelerate Gene Therapy Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
Krystal Biotech is trying to turn a one‑product story into a broader business, with planned launches outside the US and several new programs that could widen its reach. The catch is that today it still leans heavily on its lead skin treatment, and shifts in patient use, reimbursement decisions, or new gene‑therapy rivals could quickly change the outlook.Read more
AN
US$322.78
5.0% undervalued intrinsic discount
Fair Value
Revenue
34.51% p.a.
Profit Margin
56%
Future PE
21.62x
Price in 2029
US$394.7
Uncertain Gene Therapy Dynamics Will Fuel Challenges Yet Spark Hope
Key Takeaways Reliance on Vyjuvek faces challenges from unpredictable patient treatment patterns, pricing pressures, and reimbursement risks, impacting both revenue visibility and long-term margin stability. Expanding into new indications through the pipeline and broader patient access drives costs and risk, particularly given high R&D investment and dependence on successful clinical outcomes.Read more
AN
US$241
27.2% overvalued intrinsic discount
Fair Value
Revenue
27.01% p.a.
Profit Margin
38.89%
Future PE
28.67x
Price in 2029
US$293.75
Aging Populations And AI Will Accelerate Gene Therapy Adoption
Key Takeaways Rapid market penetration and strong operational scalability for VYJUVEK are expected to substantially increase revenue, margins, and earnings power beyond current analyst expectations. Robust pipeline progress, first-mover advantages, and AI-driven patient engagement initiatives could unlock multiple high-margin revenue streams and greater long-term growth.Read more
AN
US$371
17.4% undervalued intrinsic discount
Fair Value
Revenue
52.68% p.a.
Profit Margin
68.39%
Future PE
14.4x
Price in 2029
US$450.97
Trending Discussion
Recently Updated Narratives
AN
KRYS: Future Returns Will Reflect UK Approval And Debated Execution Risks
Fair Value: US$322.78 5.0% undervalued intrinsic discount
25 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Oncology Immunotherapy RMAT And Respiratory Programs Will Test Rare Disease Optimism
Fair Value: US$241 27.2% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Future CF And Ophthalmology Readouts Will Drive Long Term Upside
Fair Value: US$371 17.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Krystal Biotech, Inc. Key Details
About KRYS
- Founded
- 2016
- Employees
- 295
- CEO
- WebsiteView website
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
